ACTG:A5223 SEX DIFFS IN LOPINAVIR/RITONAVIR PHRMCOKIN AMNG HIV1 INFCTD MEN&WOMEN

ACTG:A5223 洛匹那韦/利托那韦 PHRMCOKIN AMNG HIV1 INFCTD 男性的性别差异

• 批准号: 7377857
• 负责人: MONICA CARTEN
• 金额: $ 0.37万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7377857
• 关键词: ACTG; A5223; SEX; DIFFS; LOPINAVIR

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study will look at drug levels in the blood in both men and women taking Kaletra¿ (also known as lopinavir/ritonavir) to see if they are different. This study will also try to find out how factors such as age, weight, race/ethnicity, and other medications may affect these drug level results. Recent scientific studies have suggested that more and more women are being infected with the HIV virus. It is thought that half of all the people in the world living with HIV/AIDS are women. However, most of the initial research studies on the safety and effectiveness of drugs used for treatment of HIV infection did not include a lot of women. Recent research suggests that HIV medications may affect men and women differently.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。这项研究将观察服用Kaletra（也称为洛匹那韦/利托那韦）的男性和女性血液中的药物水平，看看它们是否不同。本研究还将尝试找出年龄、体重、种族/民族和其他药物等因素如何影响这些药物水平结果。 最近的科学研究表明，越来越多的妇女感染了艾滋病毒。据认为，世界上感染艾滋病毒/艾滋病的人中有一半是妇女。然而，大多数关于用于治疗艾滋病毒感染的药物的安全性和有效性的初步研究并没有包括很多妇女。最近的研究表明，艾滋病毒药物可能会影响男性和女性不同。